Evidence map›Paper›PMID 34063178›Full record

ArticleVaccines2021

Differential Antibody Response against Conformational and Linear Epitopes of the L1 Proteins from Human Papillomavirus Types 16/18 Is Observed in Vaccinated Women or with Uterine Cervical Lesions.

Adolfo Pedroza-Saavedra, Angelica Nallelhy Rodriguez-Ocampo, Azucena Salazar-Piña, Aislinn Citlali Perez-Morales, Lilia Chihu-Amparan, Minerva Maldonado-Gama, Aurelio Cruz-Valdez, Fernando Esquivel-Guadarrama, Lourdes Gutierrez-Xicotencatl

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Adolfo Pedroza-SaavedraCentro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, 62100 Cuernavaca, Mexico.
Angelica Nallelhy Rodriguez-OcampoUnidad Académica Químico Biológicas y Ciencias Farmacéuticas, Universidad Autónoma de Nayarit, 36715 Tepic, Mexico.ORCID 0000-0003-0192-9789
Azucena Salazar-PiñaFacultad de Nutrición, Universidad Autónoma del Estado de Morelos, 62100 Cuernavaca, Mexico.ORCID 0000-0003-0800-7226
Aislinn Citlali Perez-MoralesCentro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, 62100 Cuernavaca, Mexico.
Lilia Chihu-AmparanCentro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, 62100 Cuernavaca, Mexico.ORCID 0000-0001-9999-8234
Minerva Maldonado-GamaCentro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, 62100 Cuernavaca, Mexico.
Aurelio Cruz-ValdezCentro de Investigación en Salud Poblacional, Instituto Nacional de Salud Pública, 62100 Cuernavaca, Mexico.
Fernando Esquivel-GuadarramaFacultad de Medicina, Universidad Autónoma del Estado de Morelos, 62100 Cuernavaca, Mexico.
Lourdes Gutierrez-XicotencatlCentro de Investigación Sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, 62100 Cuernavaca, Mexico.ORCID 0000-0003-1828-0007
Instituto Nacional de Salud Pública · MXUniversidad Autónoma del Estado de Morelos · MXUniversidad Autónoma de Nayarit · MX

Funding

Consejo Nacional de Ciencia y Tecnología 290022PROMEP-PIFI UAEMOR-CA-26
6 · The paper itself

Abstract

Antibodies against the Human Papillomavirus (HPV) L1 protein are associated with past infections and related to the evolution of the disease, whereas antibodies against L1 Virus-Like Particles (VLPs) are used to follow the neutralizing antibody response in vaccinated women. In this study, serum antibodies against conformational (VLPs) and linear epitopes of HPV16/18 L1 protein were assessed to distinguish HPV-vaccinated women from those naturally infected or those with uterine cervical lesions. The VLPs-16/18 were generated in baculovirus, and L1 proteins were obtained from denatured VLPs. Serum antibodies against VLPs and L1 proteins were evaluated by ELISA. The ELISA-VLPs and ELISA-L1 16/18 assays were validated with a vaccinated women group by ROC analysis and the regression analysis to distinguish the different populations of female patients. The anti-VLPs-16/18 and anti-L1-16/18 antibodies effectively detect vaccinated women (AUC = 1.0/0.79, and 0.94/0.84, respectively). The regression analysis showed that anti-VLPs-16/18 and anti-L1-16/18 antibodies were associated with the vaccinated group (OR = 2.11 × 10

Indexed as

cervical cancerHPV vaccinehuman papillomavirusL1 proteinlinear and conformational epitopesVLPs

Identifiers

PMID34063178
PMCPMC8147477
OpenAlexW3158914035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.